Return to homepagePandemic Pact

AGILE Clinical Trial Platform

  • Funded by UK Research and Innovation (UKRI)
  • Total publications:0 publications

Grant number: C19-IUC-383

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    N/A

  • Funder

    UK Research and Innovation (UKRI)

  • Principal Investigator

    Prof. Thomas Jaki

  • Research Location

    United Kingdom

  • Lead Research Institution

    MRC Biostatistics Unit

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Phase 1 clinical trial

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Clinical Trial, Phase I

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The AGILE clinical trial platform has been launched specifically to test new COVID-19 treatments, faster than ever before. AGILE is an adaptive randomized seamless Phase I/II trial platform that seeks to quickly establish a safe range of doses and investigates treatments for potential efficacy using a Bayesian sequential trial design.